-
公开(公告)号:US5374622A
公开(公告)日:1994-12-20
申请号:US10234
申请日:1993-01-28
CPC分类号: C07K14/75 , C07K5/1016
摘要: A fibrinogen receptor antagonist of the formulaAc-Cys-Asn-Pro-(L-AMF)-Gly-Asp-Cys-OHorAc-Cys-Asn-(DiMeTzl)-(L-AMF)-Gly-Asp-Cys-OH.
摘要翻译: 式Ac-Cys-Asn-Pro-(L-AMF)-Gly-Asp-Cys-OH或Ac-Cys-Asn-(DiMeTzl) - (L-AMF)-Gly-Asp-Cys的纤维蛋白原受体拮抗剂 -哦。
-
公开(公告)号:US5338723A
公开(公告)日:1994-08-16
申请号:US948331
申请日:1992-09-21
CPC分类号: C07K14/75 , C07K5/1016
摘要: A fibrinogen receptor antagonist of the formula ##STR1## wherein XX represents a synthetic alpha-amino acid containing a linear side chain and ZZ represents a sequence of 1, 2, 3 or 4 amino acids.
摘要翻译: 一种下式的纤维蛋白原受体拮抗剂,其中XX代表含有线性侧链的合成α-氨基酸,ZZ代表1,2,3或4个氨基酸的序列。
-
公开(公告)号:US5091366A
公开(公告)日:1992-02-25
申请号:US534001
申请日:1990-06-04
摘要: Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro, HAr-Pro, Dly-Pro, Arg-Pro, Lys-BAr, Arg-Pro, CyA-CyA, Cys-Cys, or with .alpha.-aminoheptanoic acid result in analogs of ANF having increased potencies and metabolic stability.
摘要翻译: ANF的17-元环部分的类似物,其中半胱氨酸部分被二肽基部分,特别是Phe-Pro,NMP-Pro,Pro-Pro,Val-Pro,Lys-Pro,Ile-Pro,Arg-Pro, HAr-Pro,Dly-Pro,Arg-Pro,Lys-BAr,Arg-Pro,CyA-CyA,Cys-Cys或α-氨基庚酸导致ANF的类似物具有增加的效力和代谢稳定性。
-
公开(公告)号:US5061693A
公开(公告)日:1991-10-29
申请号:US386533
申请日:1989-07-28
申请人: Ruth F. Nutt , Stephen F. Brady , Daniel F. Veber
发明人: Ruth F. Nutt , Stephen F. Brady , Daniel F. Veber
摘要: A fibrinogen receptor antagonist compound of the structure:A--B--C--Gly--Asp--D--E (I)wherein A, B, C, D and E are preferably defined as follows:A is L-asparagine, D-asparagine or acylated asparagineB is an L-or D-isomer of proline, thioproline, .beta.,.beta.-dimethylthioproline, or N-methylalanine;C is arginine;D is phenylalanine, tryptophan .alpha.-naphthylalanine, .beta.-napthlalanine, arginine or lysine; andE is OH.
-
公开(公告)号:US5023233A
公开(公告)日:1991-06-11
申请号:US386395
申请日:1989-07-28
申请人: Ruth F. Nutt , Stephen F. Brady , Daniel F. Veber
发明人: Ruth F. Nutt , Stephen F. Brady , Daniel F. Veber
摘要: A fibrinogen receptor antagonist of the formula: ##STR1## wherein A, B, C, D, E, R, R.sup.1 and X-Y are preferably defined as follows:A is acylamido;R and R.sup.1 are H;X-Y is S--S;B is L-asparagine;C is proline or thioproline or .beta., .beta.-dimethylthroprolineD is arginine; andE is COOH.
-
公开(公告)号:US5672582A
公开(公告)日:1997-09-30
申请号:US322049
申请日:1994-10-12
申请人: Daniel F. Veber , S. Dale Lewis , Jules A. Shafer , Dong-Mei Feng , Ruth F. Nutt , Stephen F. Brady
发明人: Daniel F. Veber , S. Dale Lewis , Jules A. Shafer , Dong-Mei Feng , Ruth F. Nutt , Stephen F. Brady
IPC分类号: C07D211/36 , A61K31/16 , A61K31/19 , A61K31/215 , A61K31/40 , A61K31/445 , A61K38/00 , A61P7/02 , A61P43/00 , C07C237/10 , C07C271/22 , C07D207/16 , C07D211/60 , C07K5/02 , C07K5/06 , C07K5/065 , C07K5/087 , A61K38/05
CPC分类号: C07K5/0812 , C07K5/0202 , C07K5/06078 , C07K5/06191 , A61K38/00
摘要: 4-substituted cyclohexylamine derivatives which are thrombin catalytic site inhibitors and which are useful as anticoagulants. These compounds show selectivity for thrombin over other trypsin-like enzymes and have oral bioavailability. They have the formula ##STR1## for example ##STR2##
摘要翻译: 4-取代的环己胺衍生物,它们是凝血酶催化位点抑制剂,可用作抗凝剂。 这些化合物显示凝血酶比其它胰蛋白酶样酶具有选择性并具有口服生物利用度。 它们具有公式
,例如 -
公开(公告)号:US5204328A
公开(公告)日:1993-04-20
申请号:US789378
申请日:1991-11-05
摘要: Atrial natriuretic factor analogs containing N-alkylated amino acids and showing enhanced potency and increased metabolic stability. These analogs have natriuretic, diuretic and vasorelaxant activity, making them suitable for treating congestive heart failure and renal hypertension.
摘要翻译: 含有N-烷基化氨基酸的心房利钠因子类似物,显示出增强的效力和增加的代谢稳定性。 这些类似物具有利钠,利尿和血管舒张活性,使其适用于治疗充血性心力衰竭和肾性高血压。
-
公开(公告)号:US5681926A
公开(公告)日:1997-10-28
申请号:US564254
申请日:1995-12-15
IPC分类号: G01N33/53 , A61K51/08 , C07K7/06 , C07K14/705 , C07K14/745 , G01N33/566 , A61K38/04 , A61K38/07 , A61K38/08 , C07K7/00
CPC分类号: C07K14/705 , A61K51/08 , A61K2123/00
摘要: Peptides having the general sequence A-B-C-D-E-F-Z wherein A is Ala, B is pFPhe, C is, for example, Arg, D is Cha, E is, for example, hArg, F is, for example, Tyr, and Z is, for example NH.sub.2. The peptides are useful for promoting wound healing and arresting bleeding in a patient.
摘要翻译: PCT No.PCT / US94 / 06672 Sec。 371 1995年12月15日第 102(e)日期1995年12月15日PCT提交1994年6月14日PCT公布。 公开号WO94 / 29338 日期为1994年12月22日具有一般序列ABCDEFZ的肽,其中A为Ala,B为pFPhe,C为例如Arg,D为Cha,E为例如hArg,F为例如Tyr和Z 是例如NH 2。 这些肽可用于促进伤口愈合并阻止患者出血。
-
公开(公告)号:US5457177A
公开(公告)日:1995-10-10
申请号:US77850
申请日:1993-06-16
IPC分类号: G01N33/53 , A61K51/08 , C07K7/06 , C07K14/705 , C07K14/745 , G01N33/566 , A61K38/08
CPC分类号: C07K14/705 , A61K51/08 , A61K2123/00
摘要: The radioligands are six amino acid peptides having iodinated tyrosine at amino acid position six, including Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH.sub.2, which mimic the activated form of the thrombin receptor protein. Thrombin receptor radioligands of the present invention are useful for screening for thrombin receptor antagonists.
摘要翻译: 放射性配体是在氨基酸位置六处具有碘化酪氨酸的六个氨基酸肽,包括模拟凝血酶受体蛋白的活化形式的Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH 2。 本发明的凝血酶受体放射性配体可用于筛选凝血酶受体拮抗剂。
-
公开(公告)号:US5057603A
公开(公告)日:1991-10-15
申请号:US571803
申请日:1990-08-23
CPC分类号: C07K14/582 , A61K38/00
摘要: Novel peptides having potent natriuretic activity are disclosed with the following amino acid sequence: ##STR1## wherein X is L-Ile, D-Ile, D-allo-Ile, L-Met or D-Met, Y is Gly, L-Ala or D-Ala, A is optionally absent or is Ser, Ser-Ser, Arg-Ser-Ser, Arg-Arg-Ser-Ser, Leu-Arg-Arg-Ser-Ser or Ser-Leu-Arg-Arg-Ser-Ser and B is optionally absent or is Asn, Asn-Ser, Asn-Ser-Phe, Asn-Ser-Phe-Arg, or Asn-Ser-Phe-Arg-Tyr, provided that at least one of Y.sup.10, Y.sup.16, Y.sup.20 or Y.sup.22 is Ala or D-Ala, and the amides, lower alkyl esters and the physiologically acceptable metal salts and acid addition salts thereof.
摘要翻译: 公开了具有有效利钠肽活性的新肽,其具有以下氨基酸序列:其中X是L-Ile,D-Ile,D-allo-Ile,L-Met或D-Met,Y是Gly,L-Ala 或D-Ala,A任选不存在或是Ser,Ser-Ser,Arg-Ser-Ser,Arg-Arg-Ser-Ser,Leu-Arg-Arg-Ser-Ser或Ser-Leu-Arg-Arg-Ser -Ser和B任选不存在,或者是Asn,Asn-Ser,Asn-Ser-Phe,Asn-Ser-Phe-Arg或Asn-Ser-Phe-Arg-Tyr,条件是Y10,Y16, Y20或Y22是Ala或D-Ala,酰胺,低级烷基酯及其生理上可接受的金属盐和酸加成盐。
-
-
-
-
-
-
-
-
-